semaglutide and neuropathy Dose-dependent Risk for Ischemic Optic Found with Semaglutide and Restless Leg Syndrome:
Description
Because retatrutide includes GLP-1 agonism (which semaglutide was providing) plus GIP and glucagon agonism, the transition should not result in loss of appetite suppression during the switch
Specific dose figures from those trials appear in the cited PMIDs (PMID 40544433, PMID 37364590) for research reference
They can induce vomiting and nausea for some patients
Across studies, fat mass decline predominated, whereas reductions in lean body mass were modest
Bland, low-fat, and easy-to-digest foods are often recommended during flare-ups
